Literature DB >> 11937541

Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223).

Susanne Andreae1, Fabienne Piras, Nicolas Burdin, Frédéric Triebel.   

Abstract

Lymphocyte activation gene-3 (LAG-3) is an MHC class II ligand expressed on activated T and NK cells. A LAG-3Ig fusion protein has been used in mice as an adjuvant protein to induce antitumor responses and specific CD8 and CD4 Th1 responses to nominal Ags. In this work we report on the effect of LAG-3Ig on the maturation and activation of human monocyte-derived dendritic cells (DC). LAG-3Ig binds MHC class II molecules expressed in plasma membrane lipid rafts on immature human DC and induces rapid morphological changes, including the formation of dendritic projections. LAG-3Ig markedly up-regulates the expression of costimulatory molecules and the production of IL-12 and TNF-alpha. Consistent with this effect on DC maturation, LAG-3Ig disables DC in their capacity to capture soluble Ags. These events are associated with the acquisition of professional APC function, because LAG-3Ig increases the capacity of DC to stimulate the proliferation and IFN-gamma response by allogeneic T cells. These effects were not observed when using ligation of MHC class II by specific mAb. Class II-mediated signals induced by a natural ligand, LAG-3, lead to complete maturation of DC, which acquire the capacity to trigger naive T cells and drive polarized Th1 responses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11937541     DOI: 10.4049/jimmunol.168.8.3874

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

Review 1.  Transcription factors in the control of dendritic cell life cycle.

Authors:  Arpita S Bharadwaj; Devendra K Agrawal
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

2.  CD70 expression by dendritic cells plays a critical role in the immunogenicity of CD40-independent, CD4+ T cell-dependent, licensed CD8+ T cell responses.

Authors:  Katherine E Van Deusen; Rohan Rajapakse; Timothy N J Bullock
Journal:  J Leukoc Biol       Date:  2009-12-01       Impact factor: 4.962

3.  LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors.

Authors:  Sandrine Buisson; Frédéric Triebel
Journal:  Immunology       Date:  2005-03       Impact factor: 7.397

4.  Effect of acetaminophen (paracetamol) on human osteosarcoma cell line MG63.

Authors:  Lourdes Díaz-Rodríguez; Olga García-Martínez; Manuel Arroyo-Morales; Belén Rubio-Ruiz; Concepción Ruiz
Journal:  Acta Pharmacol Sin       Date:  2010-11       Impact factor: 6.150

5.  The role of checkpoints in the treatment of GBM.

Authors:  Jennifer E Kim; Michael Lim
Journal:  J Neurooncol       Date:  2015-03-07       Impact factor: 4.130

6.  The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells.

Authors:  Laëtitia Maçon-Lemaître; Frédéric Triebel
Journal:  Immunology       Date:  2005-06       Impact factor: 7.397

7.  Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3(+) )-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates.

Authors:  N Poirier; T Haudebourg; C Brignone; N Dilek; J Hervouet; D Minault; F Coulon; R V de Silly; F Triebel; G Blancho; B Vanhove
Journal:  Clin Exp Immunol       Date:  2011-02-24       Impact factor: 4.330

Review 8.  LAG-3 in Cancer Immunotherapy.

Authors:  Monica V Goldberg; Charles G Drake
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

9.  LAG-3 Confers a Competitive Disadvantage upon Antiviral CD8+ T Cell Responses.

Authors:  Kevin D Cook; Jason K Whitmire
Journal:  J Immunol       Date:  2016-05-20       Impact factor: 5.422

10.  CXCL10-producing mucosal CD4+ T cells, NK cells, and NKT cells are associated with chronic colitis in IL-10(-/-) mice, which can be abrogated by anti-CXCL10 antibody inhibition.

Authors:  Udai P Singh; Shailesh Singh; Rajesh Singh; Yingzi Cong; Dennis D Taub; James W Lillard
Journal:  J Interferon Cytokine Res       Date:  2008-01       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.